RLAY Overview
Upcoming Projects (RLAY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (RLAY)
-
A third view: Digging into the P1/2 results and potential of Relay Therapeutics' FGFR2 inhibitor, RLY-4008, in cholangiocarcinoma.
Tickers: RLAY, INCY, Taiho Pharmaceuticals, QED Therapeutics
Executed On: Oct 14, 2022 at 02:00 PM EDT -
A second view: Digging into the P1/2 results and potential of Relay Therapeutics' FGFR2 inhibitor, RLY-4008, in cholangiocarcinoma
Tickers: RLAY, INCY, Taiho Pharmaceuticals, QED Therapeutics
Executed On: Oct 07, 2022 at 04:30 PM EDT -
Digging into the P1/2 results and potential of Relay Therapeutics' FGFR2 inhibitor, RLY-4008, in cholangiocarcinoma
Ticker: RLAY
Executed On: Oct 07, 2022 at 08:30 AM EDT
Upcoming & Overdue Catalysts (RLAY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (RLAY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
